Corporate ActionJun 12, 2026, 04:37 PM
Trinity Biotech enters $4.35M ATM offering with Lucid Capital
AI Summary
Trinity Biotech PLC has entered into a new At-the-Market (ATM) offering agreement with Lucid Capital Markets, LLC, enabling the company to sell up to $4,352,314 of its American Depositary Shares (ADSs). Lucid will act as the sales agent and receive a 3.0% commission on gross sales. Concurrently, the company terminated its previous ATM program with Craig-Hallum Capital Group LLC, which had been inactive since March 2025.
Key Highlights
- Trinity Biotech entered an At-the-Market (ATM) offering agreement with Lucid Capital Markets, LLC.
- The company may sell up to $4,352,314 of its American Depositary Shares (ADSs).
- Lucid Capital Markets will serve as the sales agent for the offering.
- Lucid will receive a commission equal to 3.0% of the gross sales price.
- The ADSs will be sold under a previously filed Registration Statement on Form F-3.
- Trinity Biotech terminated its prior ATM program with Craig-Hallum Capital Group LLC.
- The previous ATM program with Craig-Hallum had been inactive since March 2025.
Price Impact
More from TRIB